Perflutren is a transpulmonary echocardiographic contrast agent for use in patients with suspected or established cardiovascular disease to provide opacification of cardiac chambers, enhance left ventricular endocardial border delineation with resulting improvement in wall motion visualisation. Perflutren should only be used in patients where the study without contrast enhancement is inconclusive.
For this indication, competent medicine agencies globally authorize below treatments:
Intravenous
0.5 - 8.7 mL
From 0.5 To 8.7 mL once every day
The recommended dose is 0.5-3.0 ml per patient. A dose of 3.0 ml is usually sufficient, but some patients may need higher doses. The total dose should not exceed 8.7 ml per patient. The duration of the useful imaging time is 2.5-4.5 minutes for a dose of 0.5-3.0 ml. Perflutren could be repeatedly administered, however, the clinical experience is limited.